219 related articles for article (PubMed ID: 37675002)
1. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
4. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
5. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract][Full Text] [Related]
6. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
Paoluzzi L; Ow TJ
Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
[TBL] [Abstract][Full Text] [Related]
7. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
8. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report.
Geidel G; Rünger A; Schneider SW; Gebhardt C
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():49-52. PubMed ID: 34855252
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
O'Connell KA; Schmults CD
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
11. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
Front Oncol; 2021; 11():691980. PubMed ID: 34540666
[TBL] [Abstract][Full Text] [Related]
13. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
Mager L; Gardeen S; Carr DR; Shahwan KT
Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
[TBL] [Abstract][Full Text] [Related]
16. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
[TBL] [Abstract][Full Text] [Related]
17. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
[TBL] [Abstract][Full Text] [Related]
18. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
19. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M
Front Oncol; 2021; 11():686308. PubMed ID: 34820323
[TBL] [Abstract][Full Text] [Related]
20. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion.
Argenziano G; Fargnoli MC; Fantini F; Gattoni M; Gualdi G; Pastore F; Pellacani G; Quaglino P; Queirolo P; Troiani T
Ther Adv Med Oncol; 2022; 14():17588359211066272. PubMed ID: 35035534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]